An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210481

Enrollment

Registered

2021-12-12

Start date

2022-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Sclerosis

Interventions

Nemolizumab will be administered subcutaneously

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Diagnosis of Systemic Sclerosis according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria -Systemic Sclerosis patients with moderate to sever skin sclerosis

Exclusion criteria

Exclusion criteria: -Patients witg a disease considered inappropriate for participation in clinical trials, such as serious cardiac / hepatic / renal / pulmonary / hematologic disease -Patients with a diseases that could interfere with assessment of Systemic Scleorosis -Patients with body weight less than 30.0kg -Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Change from Baseline in modified Rodnan Skin Score (mRSS) at Week 24	—

Contacts

Public ContactClinical Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-753253279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026